Skip Navigation



NDT Advance Access published online on July 19, 2005
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfh996
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
20/10/2243    most recent
gfh996v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kawasaki, Y.
Right arrow Articles by Suzuki, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kawasaki, Y.
Right arrow Articles by Suzuki, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org
Received December 13, 2004
Accepted May 11, 2005

Brief Report

Oral mizoribine pulse therapy for patients with steroid-resistant and frequently relapsing steroid-dependent nephrotic syndrome

Yukihiko Kawasaki 1*, Mitsuaki Hosoya 1, Schogo Kobayashi 1, Shinichirou Ohara 1, Noriko Onishi 1, Ai Takahashi 1, Masato Isome 1, and Hitoshi Suzuki 1

1 Department of Pediatrics, Fukushima Medical University School of Medicine, 1 Hikariga-oka, Fukushima City, Fukushima 960-1295, Japan

* To whom correspondence should be addressed.
Yukihiko Kawasaki, E-mail: tomo{at}fmu.ac.jp



  Abstract

Background. We investigated the efficacy of oral mizoribine pulse therapy (mizoribine-pulse) for cyclosporin (CyA)-dependent, steroid-resistant nephrotic syndrome (SRNS) and frequently relapsing, steroid-dependent nephrotic syndrome (FR-SDNS).

Methods. One child with CyA-dependent SRNS and eight children with CyA-dependent FR-SDNS were treated with mizoribine-pulse (daily dose: 10 mg/kg; maximum total dose 500 mg). We compared clinical manifestations before and after mizoribine-pulse, and studied the changes in serum mizoribine concentration in each patient on days when mizoribine was administered.

Results. Four patients had no subsequent relapses (responders). Two of the four responders discontinued prednisolone and CyA, the other two discontinued CyA. Although each of the five other patients (non-responders) experienced single subsequent relapses, the dosages of prednisolone and CyA after mizoribine-pulse were decreased significantly compared with before mizoribine-pulse. The peak blood concentration of mizoribine in the responders was higher than in the non-responders (3.6±0.9 vs 1.8±0.4 µg/ml).

Conclusions. Mizoribine-pulse may be effective for some patients with CyA-dependent SRNS and FR-SDNS.

Keywords: children; clinical; mizoribine oral pulse therapy; nephrotic syndrome; steroid-resistant nephrotic syndrome.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
A. Nakajo, J. Khoshnoodi, H. Takenaka, E. Hagiwara, T. Watanabe, H. Kawakami, R. Kurayama, Y. Sekine, F. Bessho, S. Takahashi, et al.
Mizoribine Corrects Defective Nephrin Biogenesis by Restoring Intracellular Energy Balance
J. Am. Soc. Nephrol., September 1, 2007; 18(9): 2554 - 2564.
[Full Text] [PDF]

Home page
 CJASNHome page
R. J. Hogg, L. Fitzgibbons, J. Bruick, M. Bunke, B. Ault, N. Baqi, H. Trachtman, and R. Swinford
Mycophenolate Mofetil in Children with Frequently Relapsing Nephrotic Syndrome: A Report from the Southwest Pediatric Nephrology Study Group
Clin. J. Am. Soc. Nephrol., November 1, 2006; 1(6): 1173 - 1178.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
Y. Nishioka, Y. Horita, M. Tadokoro, K. Taura, N. Suyama, M. Miyazaki, T. Harada, and S. Kohno
Changing mizoribine administration from three divided doses to one single dose induced remission of relapsed membranous nephropathy
Nephrol. Dial. Transplant., August 1, 2006; 21(8): 2337 - 2338.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.